AHA Scientific Statement on Prevention of CVD Risk During Menopause Transition
Scientific statement by AHA detailing the current understanding of menopause transition and its impact on the risk for postmenopausal cardiovascular disease.
All articles by Gary Rothbard, MD, MS
Effect of Empagliflozin on Pulmonary Capillary Wedge Pressure in HFrEF
Researchers’ goal was to determine empagliflozin’s impact on the central hemodynamic parameters of patients with heart failure with reduced ejection fraction.
Examining the Efficacy of LDL-C-Lowering Therapies in Older Adults
Lipid-lowering pharmacotherapy targeting LDL-C was found to be safe and effective in reducing CV and cerebrovascular events, with similar efficacy in older and younger patients.
New Tool May Improve Prediction and Discrimination of Suspected Obstructive CAD
A novel tool in which clinical risk factors and coronary artery calcium score are added to standard pre-test probability modeling was found to improve risk prediction in suspected obstructive coronary artery disease.
Repeat vs Index Ablation for Atrial Fibrillation
Repeat catheter ablation was found to be safe and to have efficacy comparable with index ablation in alleviating symptoms in patients with atrial fibrillation.
Vericiguat Not Found to Improve Physical Limitation in HFpEF With Recent Decompensation
Treatment with vericiguat was not found to improve physical limitation in patients with HFpEF and recent decompensation.
Canagliflozin Found to Lower NT-proBNP Levels in Patients With T2DM at Risk for CVD
Canagliflozin was found to lower NT-proBNP concentrations in patients with type 2 diabetes who are at risk for cardiovascular disease.
Excellent Prognosis After Out-of-Hospital Cardiac Arrest in Patients With CAD and Normal EP
Patients with obstructive coronary artery disease or coronary spasm who suffered a nonfatal cardiac arrest outside the hospital setting and subsequently had a normal electrophysiologic study were found to have excellent prognosis.
De-escalation of Prasugrel Therapy After PCI May Reduce Clinical Outcomes in Patients With ACS
Dose de-escalation of prasugrel 1 month after percutaneous coronary intervention in patients with acute coronary syndrome was found to lower the risk for adverse clinical outcomes.
Guidelines for ACS Management During the COVID-19 Pandemic
An international group of frontline physicians formulated guidelines regarding the triage and management of patients with acute coronary syndrome during the COVID-19 pandemic.
-
Loading...
-
Loading...
